CDXC News and Press, ChromaDex Corporation From 05/08/24

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. ChromaDex Corp. (NASDAQ:CDXC) today anno...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 17:35:59 ET More on ChromaDex ChromaDex GAAP EPS of $0.00 beats by $0.02, revenue of $21.2M beats by $0.46M Seeking Alpha’s Quant Rating on ChromaDex Historical earnings data for ChromaDex Read the full article on Seeking Alpha For f...

New ingredient collaboration debuts Solgar’s first NAD + boosting supplement and reinforces NIAGEN as the gold standard in the NAD + supplement category ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and h...

Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements™ and online at vitaminshoppe.com ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces that it...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024....

Tru Niagen ® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship product, Tru Ni...

All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport ® ) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) and healthy aging research, announces that its flagship Tru Ni...

2024-03-06 23:11:06 ET ChromaDex Corporation (CDXC) Q4 2023 Earnings Conference Call March 06, 2024, 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - CEO Brianna Gerber - CFO Andrew Shao - Senior Vice President of Scient...

Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year, gross margin of 60.8%, net loss of only $4.9 million, positive Adjusted EBITDA of $1.9 million and positive operating cash flows. ...